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Abstract
Background: Observational studies and randomized trials have suggested that estrogens and/or progesterone may
lower the risk for colorectal cancer. Inherited variation in the sex-hormone genes may be one mechanism by
which sex hormones affect colorectal cancer, although data are limited.
Method: We conducted a comprehensive evaluation of single nucleotide polymorphisms (SNPs) in genes
encoding 3 hormone receptors (ESR1, ESR2, PGR) and 5 hormone synthesizers (CYP19A1 and CYP17A1, HSD17B1,
HSD17B2, HSD17B4) among 427 women with incident colorectal cancer and 871 matched controls who were
Caucasians of European ancestry from 93676 postmenopausal women enrolled in the Women’s Health Initiative
Observational cohort. A total of 242 haplotype-tagging and functional SNPs in the 8 genes were included for
analysis. Unconditional logistic regression with adjustment for age and hysterectomy status was used to estimate
odds ratios (ORs) and 95% confidence intervals (CIs).
Results: We observed a weak association between the CYP17A1 rs17724534 SNP and colorectal cancer risk (OR per
risk allele (A) = 1.39, 95% CI = 1.09-1.78, corrected p-value = 0.07). In addition, a suggestive interaction between
rs17724534 and rs10883782 in 2 discrete LD blocks of CYP17A1 was observed in relation to colorectal cancer
(empirical p value = 0.04). Moreover, one haplotype block of CYP19A1 was associated with colorectal cancer
(corrected global p value = 0.02), which likely reflected the association with the tagging SNP, rs1902584, in the
block.
Conclusion: Our findings offer some support for a suggestive association of CYP17A1 and CYP19A1 variants with
colorectal cancer risk.
Background
Epidemiologic studies have consistently shown that an
increase in female hormones such as estrogens and pro-
gestin as a result of pregnancy or use of exogenous ster-
oid hormones is associated with a lower risk for
developing colorectal cancer [1-3]. In support of these
findings, the Women’s Health Initiative (WHI) estrogen
plus progestin (E+P) clinical trial reported a 40% lower
risk for colorectal cancer in the treatment group com-
pared with the placebo group [4,5]. By contrast, the other
WHI estrogen-alone (E-alone) trial among hysterecto-
mized women did not find a lower risk of colorectal can-
cer in the treatment group [6]. Two recent observational
studies also reported no reduced risk for colorectal can-
cer incidence among postmenopausal women with higher
circulating levels of estradiol and estrone [7,8]. Findings
from these studies seemingly suggest that progesterone,
but not estrogen, may be the key candidate for risk
reduction in colorectal cancer. Alternatively, the risk
associated with sex hormones may be under genetic con-
trol, as these hormones bind to their respective receptors
to exert biological actions in target tissues such as the
colorectum. Genes responsible for sex-hormone synthesis
and metabolism also affect changes in sex hormone con-
centrations, and variation in these genes may affect risk
for disease development.
Few candidate-gene studies have evaluated variation in
sex-hormone genes in relation to colorectal cancer risk
and findings have been mixed. Some [9,10] but not all
[11,12] studies reported a potential link between genetic
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development. To date, at least 3 phase-design genome-
wide association scan (GWAS) studies of colorectal can-
cer have been undertaken, which identified several novel
susceptibility loci mapping to 1q41, 3q26.2, 8q23.3,
8q24, 10p14, 12q13.13, 14q22.2, 15q13, 16q22.1, 18q21,
19q13.1, 20p12.3, and 20q13.33 [13-20]. However, none
of these detected regions harbor genes involved in sex
hormone synthesis or actions. Two of the nearest sex-
hormone genes, HSD17B2 (16q24.1) and CYP19A1
(15q21.1), are at least 13 million basepairs (bp) distant
from the GWAS loci. These observations suggest that
the individual effect of hormone-related genes on color-
ectal cancer risk is not large enough to be detected at
the genome-wide significance level (ie, p value <10
-7 to
10
-8). Although the association of colorectal cancer with
sex hormone genes may be weak at an individual level,
the overall association may be enhanced if the contribu-
tions attributable to individual loci are combined
[21,22]. In addition, the association of colorectal cancer
risk with sex hormone genes may also be affected by
potential modifiers such as hormone therapy (HT) use
[10,23] and BMI [24].
In this case-control study nested in a large cohort of
postmenopausal women, we undertook a comprehensive
evaluation of common and putative functional variants in
the genes encoding estrogen and progesterone receptors
(ESR1, ESR2, PGR) and enzymes responsible for critical
steps in the conversion of progesterone or androgens to
estrogens (CYP19A1 and CYP17A1) and in the formation
of active estrogens (HSD17B1, HSD17B2, HSD17B4)i n
relation to colorectal cancer risk. We additionally tested
the combined effects of multiple loci on colorectal cancer
risk and evaluated effect modification by several risk
modifiers on the association between sex hormone genes
and disease risk.
Methods
Study population
We conducted a case-control study nested in the
Women’s Health Initiative Observational cohort (WHI-
OS), a large, multifaceted study designed to advance our
understanding of the determinants of major chronic dis-
eases in 93,676 postmenopausal women aged 50 to 79
years who were recruited at 40 different clinical centers
across the United States between October 1, 1993 and
December 31, 1998 [25]. At baseline, women provided
informed consent and completed questionnaires regard-
ing demographic and behavioral factors, medical history,
and use of medications including HT. A physical exami-
nation was conducted that included measurements of
height and weight and circumferences of the waist and
hip. Blood samples were obtained following an overnight
fast of at least 8 hours, and were immediately centri-
fuged and stored at -70°C.
Each year, participants were asked whether they had
been newly diagnosed with colorectal cancer. Case sta-
tus and detailed diagnosis were then confirmed through
centralized review of all pathology reports, discharge
and consultant summaries, operative and radiology
reports, and tumor registry abstracts. As of September
12 2005, 472 women of European ancestry were identi-
fied with a confirmed diagnosis of colorectal cancer.
Controls were matched to cases with a ratio of 2:1 fre-
quency on age at screening for participation in the
WHI-OS at baseline, ethnicity, hysterectomy status, and
prevalent conditions at baseline. A total of 24 (9 cases
and 15 controls) with insufficient or lack of DNA were
subsequently excluded from the analysis. We addition-
ally excluded 16 women who had reported a cancer his-
tory at baseline, which yielded a total of 460 cases and
916 controls in the present analysis.
In our exploratory analysis, we examined whether the
potential association of sex hormone genes and colorec-
tal cancer might be generalized to other ethnic groups.
We included 58 African Americans with a confirmed
diagnosis of colorectal cancer and 116 matched controls,
all of whom were free of cancer history at baseline, from
the WHI-OS for the analysis.
Written informed consent was obtained from all parti-
cipants in this study, and the study protocols were
reviewed and approved by the Brigham and Women’s
Hospital Institutional Review Board.
Single nucleotide polymorphism (SNP) selection
We first selected a set of tagging SNPs that capture
common variation and linkage disequilibrium (LD)
structure across each of the 8 hormone genes based on
the studies from the Breast and Prostate Cohort Consor-
tium project (BPC3), which has performed SNP discov-
ery and dense genotyping to capture most common
haplotype diversity in 70 American Caucasians (http://
www.uscnorris.com/MECGenetics). The tagging SNPs,
chosen from common SNPs with a minor allele fre-
quency (MAF) of 1% or greater among whites, predicted
an Rh
2 of 0.70 or greater between observed haplotypes
and those predicted based on tagging SNP genotypes
[26-30]. Altogether, 179 SNPs were selected from the 8
genes.
We next undertook a literature search to identify
putative functional SNPs in the selected genes that had
been associated with risk of cancers including colorectal
cancer. Most of these chosen SNPs were either at cod-
ing (synonymous or nonsynonymous) or promoter
regions. We identified a total of 17 SNPs from the
CYP19A1, HSD17B4, ESR1, ESR2, and PGR genes.
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ger program implemented in Haploview software [31] to
identify additional SNPs within the gene regions as well
as 10-20kb upstream and downstream of each gene and
forced in both the tagging SNPs identified by the BPC3
studies and the functional SNPs selected from the litera-
ture. The data source for tagging SNP selection was
from the CEPH Utah residents with European ancestry
in the International Hapmap Project on the National
Center for Biotechnology Information Build 35 assembly
available in July 2006 (http://www.hapmap.org). Selec-
tion of tagging SNPs was based on a pairwise correlation
coefficient (r
2) of 0.7 or greater between tagging SNPs
and untyped SNPs and a MAF of 5% or greater in the
CEPH population. As a result, we selected additional 76
tagging SNPs from the 8 genes (Table 1), yielding a
total of 272 SNPs for subsequent genotyping.
Genotyping
DNA was extracted from the buffy coat fraction of cen-
trifuged blood using the QIAmp Blood Kit (Qiagen,
Chatsworth, CA). Genotyping determination was per-
formed with the Sequenom MassARRAY Genotyping
system at the Partners Genotyping Facility (Boston,
MA). Briefly, a multiplexed PCR and then a minisequen-
cing reaction were performed in a single well. The size
of reaction products was determined directly by
MALDI-TOF mass spectrometry, yielding genotype
information. Laboratory personnel were blinded to case-
control status. Quality control (QC) of Sequenom Geno-
typing was carried out by repeating the genotyping on
66 duplicate samples with an average concordance rate
of 99.7% in all typed SNPs. The average genotyping
drop-out rates for all SNPs were 4.3%, ranged from 0.6%
to 17.5%.
Statistical Analysis
Genotype quality and filtering were first performed
using the genetic software, PLINK version 1.07 [32].
SNPs were excluded from further analysis if they had a
MAF of <5% or deviated from Hardy-Weinberg equili-
brium (HWE) among control subjects (p < 0.001). We
also excluded individuals with >20% of missing genotype
data.
Genotyping data were then analyzed with uncondi-
tional logistic regression as implemented in PLINK to
calculate odds ratios (ORs) and 95% confidence intervals
(CIs) as risk estimates for colorectal cancer in subjects
with a linear (log-odds additive) scoring for 0, 1, or 2
copies of the minor allele of each SNP. The analyzed
models were adjusted for age (continuous) and hyster-
ectomy status (yes, no) to reflect our case-control
matching design. An empirical p value was calculated
that gave a pointwise estimate of the significance level
of each SNP; a value of <0.05 was denoted statistical
significance.
Haplotype blocks were constructed for gene regions
tagging ≥1 SNP with an allelic association test p value
of <0.05. We first examined pairwise LD among controls
and determined the LD blocks for these SNPs using the
‘solid spine of LD’ algorithm implemented in Haploview.
Haplotype frequency and expected haplotypes for each
subject were then inferred based on the unphased geno-
type data using the expectation-maximization (EM)
algorithm in PLINK. We usedu n c o n d i t i o n a ll o g i s t i c
regression to estimate haplotype-specific ORs with the
rest of the haplotypes as the referents. Haplotypes with
estimated frequency of <1% were excluded from the
analysis. We also performed an omnibus test to obtain a
global p value for each haplotype block.
The possible joint effects of variation in each of the 8
genes on colorectal cancer risk were evaluated using the
set-based tests implemented in PLINK. Within each
gene, the set-based tests first selected the best SNP based
on test statistic followed by SNPs in order of decreasing
statistical significance. The statistic for each set (or each
gene) with selected SNPs is calculated by averaging the
test statistics from the selected SNPs within each gene. In
the present analysis, we allowed the PLINK to choose
simultaneously up to 5 independent loci (r
2<0.5) with
Table 1 Characteristics of the selected sex-steroid synthesizing enzymes and receptors
Gene Chromosome Covered region (in bp) # of tested SNPs
1 LD blocks
2
CYP17A1 10q24.3 104562266-104595511 11 2
CYP19A1 15q21.1 49269214-49434085 45 5
HSD17B1 17q11-q21 37943139-37970046 6 2
HSD17B2 16q24.1-q24.2 80608616-80698062 16 4
HSD17B4 5q21 118797197-118889612 7 2
ESR1 6q25.1 151999305-152477851 121 22
ESR2 14q23.2 63750946-63838055 11 2
PGR 11q22-q23 100396881-100529492 25 4
1. SNPs with Hardy-Weinberg equilibrium and a minor allele frequency of ≥5% in the Women’s Health Initiative Observational Cohort (WHI-OS) study Caucasians.
2. From the WHI-OS Caucasian controls.
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cance with 10,000 permutations.
We also assessed effect modifiers including age (<70,
≥70 years), BMI (<25, ≥25 kg/m2), HT use (current E-
alone users, current E+P users, past, never), and physical
activity (<median, ≥median METs/wk) on the genetic
association with colorectal cancer risk. We performed
unconditional logistic regression analysis according to
these factors with adjustment for the covariates
described above. We also performed a global likelihood
ratio test with a comparison of the log likelihood of the
two models with and without the interaction terms in
SAS version 9.0 (SAS Institute Inc, Cary, NC).
To control for comparisons for multiple SNPs (or hap-
lotypes), we performed 10,000 permutations to generate
a gene-specific (familywise) empirical p value for each
SNP (or haplotype) and to determine how frequently the
identified association would occur by chance. For each
permutation, the case-control status was shuffled, and
the maximum observed x
2 test statistic was compared
with the experimental test statistics for each SNP (or
haplotype). As compared with the asymptotic testing, the
permutation procedures are not restricted to the assump-
tions of normality and Hardy-Weinberg equilibrium and
are unaffected by rare allele frequency and small sample
sizes. We performed these permutations using the max
(T) permutation option in PLINK. In addition, we calcu-
lated the false discovery rate (FDR) for the global tests of
interaction analysis on each gene using SAS procedure
PROC MULTTEST [33].
In the present analysis, power to detect associated
SNPs of a MAF of 10% with relative risks of 1.3, 1.4,
1.5, and 1.7 would be 13%, 27%, 46%, and 80%, respec-
tively, using a 2-sided test and a p value of 0.001.
Results
Twenty-two of the 272 SNPs were first removed because
of an MAF of <5%. An additional 8 SNPs were excluded
because the distribution of the genotypes deviated from
HWE among controls (p < 0.001). The remaining 242
SNPs were included for further analysis (Additional file
1, Table S1). We also excluded 78 individuals with >20%
of missing genotype data, resulting in a total of 1298
women in the present analysis.
Table 2 provides the comparison of baseline charac-
teristics of colorectal cancer patients and control sub-
jects. Compared with control subjects, cancer patients
tended to be heavier, physically inactive, consumed
fewer calories, and were less likely to receive screening
exams. However, difference in distribution was not sta-
tistically significant between cases and controls with
respect to current smoking, history of colon polyps,
family history of colorectal cancer, alcohol intake, and
current use of E-alone or E+P therapy.
Among the 242 SNPs evaluated, rs10883782 and
rs17724534 in CYP17A1, rs9340837 in ESR1,a n d
rs1902584 in CYP19A1 were associated with colorectal
cancer risk with an empirical p value of <0.05 (Table 3).
When multiple comparisons were accounted for, only
the CYP17A1 rs17724534 variant remained marginally
significant (OR per copy of the risk allele (A) = 1.39,
95% CI = 1.08-1.78, corrected p-value = 0.07). There
was no interaction between gene variants and BMI,
types of HT, age, and physical activity in relation to col-
orectal cancer risk (corrected p values for interaction
≥0.14). There was also no association between gene var-
iants and colorectal cancer risk according to tumor loca-
tion and stage (data not shown).
Haplotype analysis was performed for the CYP17A1,
CYP19A1, and ESR1 genes which included ≥1S N Pw i t h
an empirical p value of <0.05. The 5
th b l o c ko ft h e
CYP19A1 gene, which contains the promoter region with
8 tagging SNPs including rs1902584, was significantly
associated with colorectal cancer risk (corrected global p
value = 0.02). Specifically, the TCCGCCGT (OR = 0.51,
95% CI = 0.34-0.7) and ATCGCTGT (OR = 1.51, 95% CI
= 1.13-2.01) haplotypes were associated with colorectal
cancer risk (Additional file 2, Table S2). The LD blocks
Table 2 Baseline characteristics (mean or %) among
colorectal cancer cases and control subjects of
Caucasians from the Women’s Health Initiative
Observational Cohort
Characteristics Cases
(N = 427)
Controls
(N = 871)
Pvalue
Age, year 66.6 66.6 Matched
Body mass index, kg/m
2 27.9 26.9 0.001
Family history of colorectal cancer, % 18.7 14.8 0.07
Colonoscopy/sigmoidoscopy exam, % 50.0 57.6 0.01
History of colorectal polyps, % 20.0 19.5 0.89
Hysterectomy, % 35.4 34.9 Matched
Current smoking, % 11.2 10.6 0.82
Current use of E-alone therapy, % 19.7 24.0 0.06
Current use of E+P therapy, % 15.7 21.2 0.06
Physical activity, MET/week 12.4 14.4 0.009
Alcohol intake, drink/day 0.07
never/past 22.2 26.0
<1 38.9 30.8
≥1 38.9 43.2
Total calorie intake, g/day 1437 1556 0.001
Tumor location
colon, N 338 N/A
rectum, N 58 N/A
Tumor stage
Localized, N 183 N/A
Regional, N 152 N/A
Distant, N 61 N/A
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with colorectal cancer risk (global p values ≥0.19).
We further evaluated the joint effects of independent
loci on colorectal cancer risk. We found that the com-
bined effects of rs10883782 and rs17724534 in CYP17A1
were significantly associated with colorectal cancer risk
(empirical p value = 0.04). Around 24% of women car-
ried ≥1 copy of the rs10883782 T allele and ≥1c o p yo f
the rs17724534 A allele. Carriers who had both of these
risk alleles were at a much greater risk of colorectal can-
cer (OR per copy of both risk alleles (T and A) = 4.60,
95% CI = 2.10-10.1). However, the LD for these 2 SNPs
was low (r
2 = 3%).
We also examined whether findings of the 4 SNPs with
pointwise significance in Caucasians might also be present
in African Americans. The risk allele, A, of the CYP17A1
rs1772453 SNP was rare (MAF = 3%) in this ethnic group,
which was not associated with colorectal cancer risk. Simi-
larly, there was no association with the rest 3 SNPs in this
ethnic group (p values ≥0.32) (Table 3).
Discussion
In this study of common and coding variation in 3 sex
hormone receptors (ESR1, ESR2, PGR) and 5 hormone-
synthesizing enzymes (CYP17A1, CYP19A1, HSD17B1,
HSD17B2, HSD17B4) in relation to colorectal cancer
risk among WHI-OS women of European ancestry, we
observed suggestive evidence for an association with the
rs17724534 SNP in CYP17A1. The association with col-
orectal cancer was more pronounced when the risk
attributable to this SNP was combined with that of
another SNP (rs10883782) in the same gene. In addition,
an LD block in CYP19A1 which includes the promoter
region was significantly associated with risk for colorec-
tal cancer. There was, however, little evidence for an
association of variation in other genes with colorectal
cancer risk. The overall genetic association was also not
affected by modifying factors including HT use, BMI,
physical activity, and age. Moreover, the null association
seen in African Americans is not surprising given that
power is also very limited in this group of women.
The biological activity of estrogen signaling in the
colon remains unclear. Several rodent and cell line stu-
dies have shown that estrogen-activated signaling
through estrogen receptor alpha and/or estrogen recep-
tor beta exhibits growth inhibition effects on colon can-
cer cells and loss of either receptors has been detected
in colorectal cancer [34-38]. It has also been suggested
that estrogen (ie, estradiol) upregulates mismatch repair
genes in colonic epithelium cells which coordinate the
repair of nucleotide base mismatches [39,40]. However,
other cell line studies have suggested the proliferative
activity of estrogens in colon cancer cells [41,42]. A
recent study of human colon carcinoma has also
reported that local synthesized concentrations of estro-
gens were 2-fold higher in colon carcinoma than those
in adjacent normal colonic mucosa and were associated
with adverse clinical outcome of the patients [43]. These
observations suggest thate s t r o g e n sm a yh a v ed u a l
effects on colorectal cancer development.
Little is known about the mechanism by which pro-
gesterone prevents colorectal carcinogenesis. It has been
Table 3 Variation in sex-steroid hormone synthesizing enzymes and receptor in relation to colorectal cancer risk in
the Women’s Health Initiative Observational Cohort
Gene/Variant N total (case/control) MAF %
1 (case/control) OR (95% CI)
2 Ptrend
3 corrected Ptrend
4
CYP17A1
rs10883782 410/834 15/18 0.78 (0.61-0.98) 0.03 0.22
rs17724534 406/829 15/12 1.39 (1.08-1.78) 0.009 0.07
CYP19A1
rs1902584 410/811 6/5 1.45 (1.07-1.98) 0.02 0.36
ESR1
rs9340837 424/866 12/9 1.37 (1.05-1.79) 0.02 0.73
CYP17A1
rs10883782 47/102 17/13 1.40 (0.72-2.73) 0.32 0.92
rs17724534 50/103 1/4 0.22 (0.03-1.74) 0.12 0.72
CYP19A1
rs1902584 52/108 6/7 0.79 (0.28-2.25) 0.67 0.99
ESR1
rs9340837 52/107 46/46 1.02 (0.64-1.62) 0.95 0.99
1. MAF = minor allele frequency.
2.For each variant, odds ratios are per copy of the risk allele.
3. Pointwise 10,000 permutation tests.
4. Familywise 10,000 permutation tests.
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one at high concentrations resulted in inhibition of
colon cancer growth [38]. In addition, a lower expres-
sion of PGR has been reported in tumors than in nor-
mal colorectal mucosa [44]. Progesterone may also
enhance the estrogenic effects on cells [45] and inhibit
the mitogenic activity of IGFs, possibly through the reg-
ulation of IGFBP1 [46-48].
Few candidate-gene studies have evaluated variation in
hormone receptors (ESR1, ESR2, PGR) in relation to col-
orectal cancer risk [9-12]. Two studies have reported an
association with ESR1 (rs9340799) and ESR2
(rs1255953) variants [9,10], whereas our study along
with two other studies [11,12] did not observe such an
association. As common variants likely confer a small
risk for disease development [21,22], studies with larger
sample sizes than the current study may be required for
the detection of significant association between sex hor-
mone receptor genes and colorectal cancer [49]. In addi-
tion, our study may be underpowered to observe an
association with variants in key enzymes involved in the
formation of active estrogens (17beta-HSD families).
Future large consortium studies may help shed light on
the relationship between these gene variants and color-
ectal cancer.
The CYP17A1 gene encodes cytocrome P450C17alpha,
an enzyme with 17 alpha-hydroxylase and 17,20-lyase
activities at key points in the biosynthesis of androgens
and estrogens via progesterone [50]. A change of T®C
variant (rs743572) located in the CYP17A1 promoter
region has been found to create a SP1-type (CCACC)
promoter site [51] and the C allele is associated with
increased CYP17 expression levels [52,53]. It has further
been suggested that the CYP17A1 C allele is associated
with enhanced production of all steroid hormones
including progesterone and estrogen because of
increased steroidogenesis in premenopausal women
[54,55], although the association is much weaker in
postmenopausal women [56]. In agreement with a pre-
vious case-control study of middle-aged men and
women [11], we did not find an association between this
SNP and colorectal cancer risk. However, rs17724534, a
neighboring SNP which is in LD with rs743572, was
found to be suggestively associated with colorectal can-
cer risk. In this study population, all women who carried
the rs17724534 A allele also had T allele of rs743572,
suggesting that the rs17724534 A allele may be asso-
ciated with lower progesterone and estrogen levels, lead-
ing to an increased risk for colorectal cancer.
We also observed a significant interaction between
rs17724534 and rs10883782 in the CYP17A1 gene on
colorectal cancer risk. The A allele of rs17724534 paired
with T allele of rs10883782 were associated with a
much greater risk for colorectal cancer as compared
with other alleles. It is possible that the rs10883782 T
allele enhanced the risk associated with the rs17724534
A allele on colorectal cancer development. To date, the
functional relevance of rs10883782 to colorectal cancer
risk is unknown, although it has been suggested that
rs10883782 is near or within a region showing sequence
homology to a CCAAT/enhancer protein, which is
known to be a strong transcription regulator [57]. Both
SNPs, which are 21.6k bp apart and not in LD, belong
to 2 discrete haplotype blocks in this study population.
After menopause, estrogen biosynthesis takes place
predominantly in adipose tissue and is catalyzed by the
aromatase enzyme, encoded by the CYP19A1 gene,
which converts androgens to estrogens. In the present
study, a haplotype block (block #5 in our analysis) in
CYP19A1 was associated with colorectal cancer, with 2
haplotypes reaching pointwise significance levels. The
risk estimates in one haplotype (ATCGCTGT) were
similar to those from the tagging SNP (rs1902584) in
this block with the minor allele (A) showing an elevated
risk for colorectal cancer, suggesting that the observed
association with this haplotype block likely reflects that
with rs1902584. The rs1902584 SNP is near the promo-
ter 1.4 region that regulates the transcription of the aro-
matase gene [24,58,59], thereby affecting circulating
hormone levels. It has been suggested that the minor
allele genotypes (AT or AA) are associated with higher
estrogen levels as compared with the homozygous major
allele genotype (TT) in overweight postmenopausal
women [60], suggesting a potential link between the
minor allele (A) and elevated estrogens from the adipos-
ity. It is possible that our finding of the associated
increased risk for colorectal cancer with the minor allele
may be attributable to obesity-induced elevation of
estrogen levels. We, however, observed no effect modifi-
cation by BMI on the association with this SNP, likely
due to a lack of power.
There are several limitations of the present study. First,
the genotyped SNPs may not sufficiently cover the entire
gene regions. Although we have chosen a commonly
used selection threshold (r
2 ≥70%) for tagging SNP selec-
tion and have also included several functional SNPs, we
cannot rule out the possibility that other untyped variants
m a yc o n t r i b u t et ot h er i s ko fd e v e l o p i n gc o l o r e c t a l
cancer. In addition, the current data focused only on
common SNPs without assessing the potential contribu-
tions of rare variants. However, if rare variants are to be
discovered with an increase in sample size, it is possible
that unidentified variants will have increasingly small
effects [61]. Moreover, we may have limited statistical
power for analysis of most of our candidate genes. Power
is also limited in this study for subgroup analysis accord-
ing to potential risk modifiers and tumor characteristics.
Finally, we do not have information on which part of the
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from, which may potentially confound the findings.
Conclusion
We observed little support for an association of gene
variants in hormone receptors (ESR1, ESR2, PGR)a n d
active estrogen synthesizers (HSD17B1, HSD17B2, and
HSD17B4) with colorectal cancer risk among postmeno-
pausal women of European descent. However, there is a
suggestive evidence for an association with variation in
CYP17A1 and CYP19A1. Our findings warrant confir-
mation in future studies.
Additional material
Additional file 1: Characteristics of the 272 SNPs. Information on
SNPs including gene name, location, alleles, and whether being included
in the analysis.
Additional file 2: Haplotype-based association of CYP19A1 with
colorectal cancer risk among the Caucasians from the Women’s
Health Initiative-Observational Cohort. Results of haplotype analysis
for the CYP19A1 gene.
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